Articles From: Retail sales data to confirm tone of holiday shopping to Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma


By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- [TK - to be prepubbed on Friday for Sunday morning - lede may have to be rewritten to account for Friday developments, please update for Friday closing prices] With gas prices at multiyear lows and consumer sentiment at multiyear highs, retail sales data will likely be the main catalyst for stocks this week.
Sign-up for Retail sales data to confirm tone of holiday shopping investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
2014/12/7
By Prudence Ho HONG KONG--The real estate arm of Wanda Group and a Chinese car maker partly owned by Daimler AG are planning to raise a combined $5.4 billion in initial public offerings in Hong Kong this month.
Sign-up for Dalian Wanda Commercial to Raise Up To $3.8 Billion in Hong Kong IPO -- Source investment picks
2014/12/7
More than 200 UnitedHealthcare employees and volunteers from the Fort Lauderdale area joined yesterday to build a new playground at Jack and Jill Children’s Center.
Sign-up for Volunteers Build Playground at Jack and Jill Children’s Center in Fort Lauderdale investment picks
Martinsried / Munich, Germany, Dec.
Sign-up for MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Monday's session are Vail Resorts Inc., H&R Block Inc., and Pep Boys.
Sign-up for UPDATE: Vail Resorts, H&R Block earnings in focus investment picks
2014/12/7
By Robb M.
Sign-up for Australian Banks Could Face Higher Capital Requirements Following Review - Update investment picks
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany , MUNICH and MONROVIA, Calif.
Sign-up for MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
2014/12/6
By Trefor Moss And Cris Larano Powerful typhoon Hagupit toppled trees, blew roofs off houses and knocked out electricity as it began it first full day of destruction in the central Philippines.
Sign-up for Typhoon Batters Philippines -- 4th Update investment picks
2014/12/6
By Robb M.
Sign-up for Australian Banks Could Face Higher Capital Requirements Following Review investment picks
2014/12/6
By Dennis Nishi Two years after becoming vice president of innovation at VF Corp., an apparel company based in Greensboro, N.C., Soon Yu was approached by one of his bosses, who quietly suggested that he do a 360-degree evaluation.
Sign-up for How to Break Your Bad Work Habits investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
2014/12/6
The future of 4K Ultra HD received a rocket-propelled boost today with the launch of a DIRECTV satellite that will deliver the new standard in TV image quality directly to viewers’ homes in the U.S., along with more HD for local markets and backup for DIRECTV’s existing fleet of six HD satellites.
Sign-up for 4K Ultra HD Gets a Lift with Successful DIRECTV Satellite Launch investment picks
2014/12/6
UnitedHealthcare and the 4-H Youth Development Program at the University of Florida are expanding a successful partnership called Eat4-Health that helps tackle obesity by promoting healthy eating and active lifestyles among youth and families.
Sign-up for Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth investment picks
2014/12/6
- Note: This press release corresponds to abstract 31.
Sign-up for IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results from a cohort of patients in its ongoing Phase 1b trial (CheckMate -039) which evaluated PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in patients with relapsed or refractory hematological malignancies (n=23). Results showed high levels of response in patients with relapsed or refractory classical Hodgkin Lymphoma (HL), with an overall response rate of 87% (n=20) and stable disease in 13% (n=3). These findings were published today in The New England Journal of Medicine ( NEJM ) and highlighted in the press briefing on Saturday, December 6 during the 56 th annual meeting of the American Society for Hematology (Abstract #289). In patients with HL, initial treatment typically consists of chemotherapy and/or radiation therapy, followed by an autologous stem cell
Sign-up for Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
CBS Corp (CBS) and Dish Network (DISH) reached an multi-year agreement on Saturday, ending a dispute that led to a short programming blackout on Friday night.
Sign-up for CBS and Dish settle fee dispute investment picks
2014/12/6
By Amy Hoak, MarketWatch 'Smart home' gadgets become more affordable and more common Homeowners are increasingly looking to technology for home security solutions, to save on heating and cooling costs and even to help them cook the perfect steak.
Sign-up for UPDATE: 5 tech gadgets you need in your home today investment picks
2014/12/6
By Amy Hoak, MarketWatch Despite decreasing affordability for houses next year, expect more home sales in 2015 -- in part due to increased purchases by millennials who are finding jobs and expanding their families.
Sign-up for UPDATE: Millennial employment, mini baby boom could lift 2015 home sales investment picks
2014/12/6
Chipotle's Arnold says the chain has "a culture where employees are trained to make what they can with the ingredients we have if a customer asks." In other words, go ahead and enjoy your Quesarito.
Sign-up for UPDATE: 10 things Chipotle won't tell you -2- investment picks
2014/12/6
By Catey Hill, MarketWatch On special today: Old produce, big markups and hygiene problems 1.
Sign-up for UPDATE: 10 things grocery stores won't tell you investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Retail sales data to confirm tone of holiday shopping to Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent